BioCentury
ARTICLE | Company News

Actelion sales and marketing update

October 29, 2012 7:00 AM UTC

Actelion disclosed in its 3Q12 earnings that in October it launched a second-generation formulation of Veletri epoprostenol in the U.S. to treat pulmonary arterial hypertension (PAH) to improve exerc...